Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-02

Clinical Trial Update: A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa [Phase 4]

View source ↗

Summary

Phase 4, double-blind, placebo-controlled trial evaluating risperidone for anorexia nervosa has completed. Results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Risperdal (risperidone)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Anorexia Nervosa | Phase 4 | Status: COMPLETED | Results posted: 2016-02-02